Reports

The generics market in China

Home/Reports | Posted 04/04/2014

Market access barriers remain the main challenge for generics in China, according to a presentation by Xianghong Shao given at the International Generic Pharmaceutical Alliance (IGPA)’s 16th Annual Conference, which was held in Brussels, Belgium, 9–11 December 2013 [1].

European doctors have insufficient knowledge of biosimilars

Home/Reports | Posted 28/03/2014

The Alliance for Safe Biologic Medicines (ASBM), which represents patients and physicians, as well as originator biological and biosimilar medicines companies in the US, published results of a survey on 18 March 2014, which showed that physicians in Europe have insufficient knowledge of biosimilars [1].

Diabetes and high blood pressure generics in Europe

Home/Reports | Posted 21/03/2014

Generics contribute value to the European Union (EU), according to a presentation by Mr Victor Lino Mendonça given at the International Generic Pharmaceutical Alliance (IGPA)’s 16th Annual Conference, which was held in Brussels, Belgium, 9–11 December 2013 [1].

The Brazilian generics market

Home/Reports | Posted 09/05/2014

Generics are an effective tool to provide affordable, safe and reliable medicines to patients in Brazil, according to a presentation by Telma Salles [1].

The generics market in Taiwan

Home/Reports | Posted 02/05/2014

Taiwan is a growing market for pharmaceuticals and the generics market is becoming more competitive in terms of price and quality, according to a presentation by Yi-Yun Wang [1].

The generics market in India

Home/Reports | Posted 25/04/2014

The profitability of generics companies in India is under pressure, according to a presentation by Mr Alok Sonig [1].

Cost savings and use of generics in Europe

Home/Reports | Posted 04/04/2014

Generics provide significant savings for the healthcare systems, as well as increased access to medicines, in the European Union (EU). This is according to a presentation by Mr Victor Lino Mendonça given at the International Generic Pharmaceutical Alliance (IGPA)’s 16th Annual Conference, which was held in Brussels, Belgium, 9-11 December 2013 [1].

FDA’s labelling proposal will increase cost of generics

Home/Reports | Posted 21/02/2014

In November 2013 the US Food and Drug Administration (FDA) proposed a new rule which would allow generics makers to change their labelling in the same way as brand-name manufacturers [1]. However, an analysis by economic consulting firm Matrix Global Advisors (MGA) shows that this change would add US$4 billion to the annual healthcare costs in the US.

Generics save US 1.2 trillion over last 10 years

Home/Reports | Posted 14/02/2014

Generics have saved consumers and the US healthcare system US$217 billion in 2012 and have saved the US in excess of US$1.2 trillion between 2003 and 2012, according to a report by the Generic Pharmaceutical Association (GPhA) [1].

Biosimilars: what physicians need to know

Home/Reports | Posted 07/02/2014

A biosimilar is a medicinal product that is similar to a biological medicinal product that has already been authorized. Biologicals are comprised of proteins, such as hormones (growth hormones, insulins, erythropoietins), enzymes, that are naturally produced in the human body, or monoclonal antibodies. Biologicals are derived through three main sources: yeast cells, bacterial cells and mammalian cells.

Giving EU Member States more freedom could increase early access to new drugs

Home/Reports | Posted 31/01/2014

A UK report urges giving European Union (EU) Member States greater freedoms to determine their own policies with respect to data protection and early access to medical innovations [1].

EU problematic patent settlements remain at low level

Home/Reports | Posted 17/01/2014

The European Commission’s (EC) fourth monitoring exercise of patent settlements in the pharmaceutical sector has shown the number of potentially problematic settlements under EU antitrust rules remain at a low level. This finding comes despite the fact that the overall number of patent settlements has increased compared to the previous monitoring periods. The EC takes this as evidence that companies can successfully settle patent disputes within the boundaries of the European Union (EU) antitrust rules.

Shortage of HIV/AIDS drugs in South Africa

Home/Reports | Posted 13/12/2013

According to a survey of South African clinics, one in five of them are running short of life-saving HIV/AIDS drugs, affecting nearly half a million people and undermining the success of the world’s largest treatment programme.

OECD report finds reduction in spending on health

Home/Reports | Posted 06/12/2013

Spending on health fell in one of three countries covered by the Organisation for Economic Co-operation and Development (OECD) between 2009 and 2011, with the countries hit hardest by the financial crisis witnessing the biggest cuts.

American-made prescription drugs 76% cheaper when purchased abroad

Home/Reports | Posted 15/11/2013

American patients can make significant savings by buying drugs abroad, according to an analysis carried out by online pharmacy information specialist PharmacyChecker.com.

Biosimilars: what patients need to know

Home/Reports | Posted 08/11/2013

Biosimilars are medicines that are similar to a biological medicine that has already been authorized. Biosimilars are different to generics in that they are not identical to their reference product. This is due to the fact that they are derived from living cells and therefore demonstrate molecular complexity and heterogeneity. For this reason biosimilars must be ‘similar but not identical’ to their reference biological with regards to quality, safety, and efficacy.

Endocrinologists need more data to prescribe biosimilars

Home/Reports | Posted 31/10/2013

Endocrinologists require more clinical trial data for biosimilars compared to other specialists, such as oncologists and gastroenterologists, according to a report from research and advisory firm BioTrends Research Group.

Gastroenterologists unlikely to use infliximab biosimilar

Home/Reports | Posted 18/10/2013

Gastroenterologists are unlikely to prescribe an infliximab biosimilar in their Crohn’s disease or ulcerative colitis patients if it has not been clinically tested in inflammatory bowel diseases, according to a report from a research and advisory firm.

Increased use of generics could save South Africa millions

Home/Reports | Posted 11/10/2013

Increasing the use of generics by 5% could save the healthcare industry and patients in South Africa in excess of Rand 400 million per year, according to a report from the country’s pharmaceutical association.

UK biosimilars uptake lower than in some other EU countries

Home/Reports | Posted 20/09/2013

Use of biosimilars in the UK is lower than might be expected when looking at the use of generics in the UK, and it is lower than in some other European countries.

Generics and biosimilars Initiative

News

Research

General